Acquisitions
Acquisitions completed from the 2025 financial year are distributed among the Group’s business areas as follows:
| Net Sales, | Number of | ||||
| Company | Country | Time | SEKm* | employees* | Business area |
| Edge Medical Ltd. | UK | April, 2025 | 90 | 20 | Medtech |
| Pharmacold A/S | Denmark | December, 2025 | 38 | 20 | Labtech |
| Opitek International ApS | Denmark | December, 2025 | 12 | 2 | Medtech |
| BioSpectrum Ltd. | UK | March, 2026 | 75 | 16 | Medtech |
| CoaChrom Diagnostica GmbH | Austria | April, 2026 | 110 | 10 | Labtech |
| 325 | 68 | ||||
| *Refers to conditions at the time of acquisition on a full-year basis. | |||||
In March all shares in BioSpectrum Ltd., United Kingdom, were acquired. BioSpectrum is a rapidly growing distributor of surgical solutions within urology, gynaecology and general surgery in the UK market. The company has annual sales of approximately GBP 6 million and 16 employees.
In April all shares in the Austrian company CoaChrom Diagnostica GmbH were acquired. CoaChrom is a distributor focusing on advanced coagulation diagnostics for clinical laboratories and the pharmaceutical industry. The company has annual sales of approximately EUR 10 million and 10 employees.
Net assets of acquired companies at the acquisition date
| Fair value | Jun 30 |
| SEKm | 2026 |
| Intangible non-current assets | 146 |
| Other non-current assets | 6 |
| Inventories | 26 |
| Other current assets | 39 |
| Deferred tax liability/tax asset | -34 |
| Other liabilities | -16 |
| Acquired net assets | 167 |
| Goodwill | 266 |
| Consideration¹ | 433 |
| Less: | |
| Cash and cash equivalents in acquired businesses | -16 |
| Contingent consideration not yet paid | -114 |
| Effect on the Group’s cash and cash equivalents | 303 |
| ¹The consideration is stated excluding acquisition expenses. |
Acquired companies
The purchase price allocations are preliminary, as the net assets of the acquired companies have not yet been finally determined. For this year’s acquisitions, the purchase consideration exceeded the carrying amount of the net assets of the acquired companies, resulting in goodwill and intangible assets.
Goodwill
The goodwill arising from the acquisition is attributable to the expectation that the Group’s position in the relevant market will be strengthened, as well as the expertise developed in the acquired companies.
Contingent consideration
The contingent considerations included in the acquisitions are usually linked to the performance development of the respective companies.
During the interim period, contingent consideration of SEK 20 million relating to acquisitions in previous years was paid to BonsaiLab and Pharmacold.
Transaction costs
Transaction costs for acquisitions amount to a total of SEK million and are recognized in selling expenses.
Revenue and earnings from acquired businesses
The acquisitions completed during the year have, from their respective acquisition dates, contributed a total of SEK 51 million to the Group’s net sales and SEK 16 million to EBITA.
Had the acquired companies been consolidated from January 1, 2026, net sales and EBITA would have amounted to SEK 98 million and SEK 37 million, respectively.
Acquisitions after the end of the interim period
No acquisitions have been completed after the end of the interim period.